[18F]FDOPA PET/CT在嗜铬细胞瘤诊断显像中优于[68Ga]DOTATOC PET/CT
该回顾性对比分析纳入113例疑似PPGL或复发患者,均行FDOPA与DOTATOC PET/CT。在97例疑似原发PPGL中,FDOPA检出全部55个PCC病灶而DOTATOC仅检出25个(灵敏度100% vs 49%,p<0.0001),FDOPA阴性预测值(100% vs 63%)和诊断准确率(98% vs 70%)更高。16例疑似复发患者中两种示踪剂诊断性能相似。
要点
- 在97例疑似原发PPGL患者中,FDOPA检出全部55个PCC病灶,DOTATOC仅检出25个(灵敏度100% vs 49%,p<0.0001)。
- FDOPA的阴性预测值(100% vs 63%,p<0.001)和诊断准确率(98% vs 70%,p<0.01)高于DOTATOC。
- FDOPA检出全部6例激素分泌性PGL患者,其中1例DOTATOC阴性;但PGL患者数量有限。
核心结论
- FDOPA在嗜铬细胞瘤(PCC)定位方面优于DOTATOC。
- 与DOTATOC不同,FDOPA也检出了全部PGL,但患者例数有限。
研究设计与样本
- 回顾性对比分析,连续纳入因疑似PPGL或PPGL复发而转诊并同时接受FDOPA和DOTATOC PET/CT检查的患者。
- 共纳入113例患者,其中97例疑似原发PPGL,16例疑似复发。
- 两名经验丰富的观察者在不知最终诊断的情况下回顾性判读两种扫描,采用视觉和定量评估。
- 最终诊断主要基于病理学。
主要发现
- 97例疑似原发PPGL患者中,51例为嗜铬细胞瘤(PCC)(共55个病灶),6例为副神经节瘤(PGL)(共7个病灶)。
- FDOPA检出并正确定位全部55个PCC,DOTATOC仅检出25个(灵敏度100% vs 49%,p<0.0001;特异度95% vs 98%,p=1.00)。
- FDOPA的阴性预测值(100% vs 63%,p<0.001)和诊断准确率(98% vs 70%,p<0.01)高于DOTATOC。
- FDOPA检出6例激素分泌性PGL中的全部6例,其中1例DOTATOC阴性。
- 16例既往PPGL疑似复发患者中,FDOPA与DOTATOC的诊断性能相似。
关键数值与推荐
- 在97例疑似原发PPGL患者中,FDOPA对PCC的灵敏度为100%(55/55),DOTATOC为49%(25/55),p<0.0001。
- FDOPA特异度为95%,DOTATOC特异度为98%,p=1.00。
- FDOPA阴性预测值为100%,DOTATOC为63%,p<0.001。
- FDOPA诊断准确率为98%,DOTATOC为70%,p<0.01。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both [18F]FDOPA (FDOPA) and [68Ga]DOTATOC PET/CT (DOTATOC) are widely used for detection of pheochromocytomas/paraganglioma (PPGL). However, direct comparisons of the performance of the two tracers are only available in small series. We conducted a retrospective comparative analysis of FDOPA and DOTATOC to assess their sensitivity and accuracy in detecting PPGL when administered based on suspicion of PPGL. We consecutively included patients referred on suspicion of PPGL or PPGL recurrence who were scanned with both FDOPA and DOTATOC. Both scans were reviewed retrospectively by two experienced observers, who were blinded to the final diagnosis. The assessment was made both visually and quantitatively. The final diagnosis was primarily based on pathology. RESULTS: In total, 113 patients were included (97 suspected of primary PPGL and 16 suspected of recurrence). Of the 97 patients, 51 had pheochromocytomas (PCC) (in total 55 lesions) and 6 had paragangliomas (PGL) (in total 7 lesions). FDOPA detected and correctly localized all 55 PCC, while DOTATOC only detected 25 (sensitivity 100% vs. 49%, p < 0.0001; specificity 95% vs. 98%, p = 1.00). The negative predictive value (100% vs. 63%, p < 0.001) and diagnostic accuracy (98% vs. 70%, p < 0.01) were higher for FDOPA compared to DOTATOC. FDOPA identified 6 of 6 patients with hormone producing PGL, of which one was negative on DOTATOC. Diagnostic performances of FDOPA and DOTATOC were similar in the 16 patients with previous PPGL suspected of recurrence. CONCLUSIONS: FDOPA is superior to DOTATOC for localization of PCC. In contrast to DOTATOC, FDOPA also identified all PGL but with a limited number of patient cases.
引用
- Iversen P, Kramer S, Ebbehoj A, et al. [18F]FDOPA PET/CT is superior to [68Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytoma. EJNMMI Res. 2023. PMID: 38110755. doi:10.1186/s13550-023-01056-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。